These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27784901)

  • 1. Targeting mutant p53 through the mevalonate pathway.
    Freed-Pastor W; Prives C
    Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.
    Kaymak I; Maier CR; Schmitz W; Campbell AD; Dankworth B; Ade CP; Walz S; Paauwe M; Kalogirou C; Marouf H; Rosenfeldt MT; Gay DM; McGregor GH; Sansom OJ; Schulze A
    Cancer Res; 2020 Jan; 80(2):189-203. PubMed ID: 31744820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The stiff RhoAd from mevalonate to mutant p53.
    Sorrentino G; Mantovani F; Del Sal G
    Cell Death Differ; 2018 Mar; 25(4):645-647. PubMed ID: 29511341
    [No Abstract]   [Full Text] [Related]  

  • 5. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHX33 mediates p53 to regulate mevalonate pathway gene transcription in human cancers.
    Nie G; Chen S; Song Q; Zou D; Li M; Tang X; Deng Y; Huang B; Yang M; Lv G; Zhang Y
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130547. PubMed ID: 38143011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
    Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
    Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.
    Ingallina E; Sorrentino G; Bertolio R; Lisek K; Zannini A; Azzolin L; Severino LU; Scaini D; Mano M; Mantovani F; Rosato A; Bicciato S; Piccolo S; Del Sal G
    Nat Cell Biol; 2018 Jan; 20(1):28-35. PubMed ID: 29255172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.
    Freed-Pastor WA; Mizuno H; Zhao X; Langerød A; Moon SH; Rodriguez-Barrueco R; Barsotti A; Chicas A; Li W; Polotskaia A; Bissell MJ; Osborne TF; Tian B; Lowe SW; Silva JM; Børresen-Dale AL; Levine AJ; Bargonetti J; Prives C
    Cell; 2012 Jan; 148(1-2):244-58. PubMed ID: 22265415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway.
    Aersilan A; Hashimoto N; Yamagata K; Yokoyama M; Nakayama A; Shi X; Nagano H; Sakuma I; Nohata N; Kinoshita T; Seki N; Rahmutulla B; Kaneda A; Zhahara SN; Gong Y; Nishimura M; Kawauchi S; Kawakami E; Tanaka T
    Sci Rep; 2022 Nov; 12(1):18443. PubMed ID: 36323841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.
    Moon SH; Huang CH; Houlihan SL; Regunath K; Freed-Pastor WA; Morris JP; Tschaharganeh DF; Kastenhuber ER; Barsotti AM; Culp-Hill R; Xue W; Ho YJ; Baslan T; Li X; Mayle A; de Stanchina E; Zender L; Tong DR; D'Alessandro A; Lowe SW; Prives C
    Cell; 2019 Jan; 176(3):564-580.e19. PubMed ID: 30580964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mevalonate metabolism in cancer.
    Gruenbacher G; Thurnher M
    Cancer Lett; 2015 Jan; 356(2 Pt A):192-6. PubMed ID: 24467965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 in cell-cell interactions.
    Pilley S; Rodriguez TA; Vousden KH
    Genes Dev; 2021 Apr; 35(7-8):433-448. PubMed ID: 33861719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
    Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
    Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and cancer stem cells: the mevalonate connexion.
    Ginestier C; Charafe-Jauffret E; Birnbaum D
    Cell Cycle; 2012 Jul; 11(14):2583-4. PubMed ID: 22751434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.